DelveInsight has launched a report on “‘Polycythemia Vera – Epidemiology Forecast to 2030”
DelveInsight’s ‘Polycythemia Vera – Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Polycythemia Vera epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Some of the Facts:
“As per DelveInsight’s analysis, the therapeutic market of Polycythemia Vera (PV) in the seven major markets was assessed to be USD 1,099.54 million in 2017”
Polycythemia Vera (PV) is a rare condition characterized by the progressively increased number of red blood cells in bloodstream, white blood cells (WBC) and platelets also increase in number in the affected people. This condition is known as myeloproliferative neoplasms, where the body produces too many of these cells (RBC, WBC and Platelets). These new cells cause the blood to be thicker than usual, increasing the risk for blood clots that can block blood flow in arteries and veins. If a blood clot occurs in the veins, deep in the arms and the legs, it is known as deep vein thrombosis (DVT).
Mutation in the JAK2 kinase is responsible for PV. Most cases of PV are associated with genetic changes that are somatic, not in the egg and sperm cells, which pass on genetic information to offspring.
The diagnosis of PV is done by testing the blood for levels of a hormone called erythropoietin or testing the blood for mutations in JAK2. Bone marrow aspiration and biopsy are also done to confirm whether or not a person has PV. The diagnostic test also includes Complete blood count (CBC) to measure the number and quality of WBCs, RBCs, and platelets.
Request for Sample Pages: https://www.delveinsight.com/sample-request/polycythemia-vera-epidemiology-forecast
Scope of the Report
KOL- Views
We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.
Key Questions Answered
Reasons to buy
Key Assessments
Related Reports:
Polycythemia Vera – Pipeline Insights, 2020
The Polycythemia Vera report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Polycythemia Vera across the complete product development cycle, including all clinical and nonclinical stages.
Polycythemia Vera Market Insight, Epidemiology and Market Forecast -2030
The Polycythemia Vera market report provides current treatment practices, emerging drugs, Polycythemia Vera market share of the individual therapies, current and forecasted Polycythemia Vera market Size from 2017 to 2030 segmented by seven major markets.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/